New cancer therapies at international conference in Amsterdam

Amsterdam/Lugano, March 16, 2006 - The 4th International Symposium on Targeted Anticancer Therapies (TAT 2006), to be held in Amsterdam, The Netherlands, March 16-18, 2006, co-organized by the NDDO Research Foundation and the European Society for Medical Oncology (ESMO), provides updates on emerging new therapies for the treatment of cancer. Several new, so-called targeted anticancer agents are likely to be approved for use in daily practice in the near future. The ones that seem closest to obtaining marketing approval in the European Union are sorafenib (Nexavar) and sunitinib (Sutent). Both are being developed for kidney cancer (renal cell cancer) and have recently been approved by the US Food and Drug Administration. European marketing applications are under review by the European Medicines Agency (EMEA).

Sorafenib and sunitinib block specific target molecules that are important for tumor growth and development. They are considered real breakthroughs in the treatment of advanced kidney cancer, a disease that is difficult to treat with currently available drugs. No new drugs for kidney cancer have been introduced in the past ten years. At TAT 2006, sorafenib and sunitinib will be reviewed extensively, in particular by Professor Martin Gore of the Royal Marsden Hospital in London, who will present a keynote lecture on emerging treatments for kidney cancer during the Opening Ceremony on March 16.

Many targeted anticancer therapies, covering a wide variety of targets in tumor tissue or the tumor's environment, are the subject of extensive research and development activities worldwide. Many targeted agents are being tested in clinical trials and are showing promising results in patients with different types of cancers. Several targeted agents have already been approved for cancer therapy by regulatory agencies worldwide, including, but not limited to, bevacizumab (Avastin), cetuximab (Erbitux) and erlotinib (Tarceva). Updates on these agents and many

Contact: Dr. Marinus W. Lobbezoo
European Society for Medical Oncology

Page: 1 2

Related biology news :

1. Protein chatter linked to cancer activation
2. Newly created cancer stem cells could aid breast cancer research
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. No evidence that widely prescribed statins protect against prostate cancer
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. New test improves detection of liver cancer
9. High-intensity ultrasound may launch attack on cancer, wherever it lurks
10. Unknotting DNA clue to cancer syndrome
11. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer

Post Your Comments:

(Date:8/1/2019)... ... 30, 2019 , ... Keck Graduate Institute (KGI) President Sheldon ... in Bioprocessing and Director of the Amgen Bioprocessing Center, effective July 29, 2019. ... possesses more than 25 years of global experience in bioprocessing,” Schuster said. "She ...
(Date:8/1/2019)... ... 01, 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice ... webinar addressing challenges with the upcoming EU MDR IVDR regulations . ... a variety of positions over his 26 years at the FDA, including developing the ...
(Date:7/24/2019)... ... July 24, 2019 , ... NDA Partners ... quality assurance expert with more than 20 years of experience working in scientific ... joined the firm as an Expert Consultant. , Dr. Hartzfeld has experience in ...
Breaking Biology News(10 mins):
(Date:7/23/2019)... , ... July 22, 2019 , ... ... companies with best-in-class services in the fields of 3D tissue imaging , ... learning , Visikol initially started back in 2013 as a products company. These ...
(Date:7/17/2019)... COLLEGE PARK, Md. (PRWEB) , ... July 15, 2019 , ... ... cut DNA so that a certain trait can be removed, replaced, or edited, but ... Maryland, is looking far beyond these traditional applications in his latest publication in Nature ...
(Date:7/11/2019)... ... July 11, 2019 , ... At the most recent ... regenerative therapies to eight military Veterans under the R3 Heroes Program. The Veterans included ... The R3 Heroes Program allow anyone to nominate a military Veteran, teacher or first ...
(Date:7/2/2019)... Calif. (PRWEB) , ... July 02, 2019 , ... Leading ... documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative ... wild animals. Animal Pharm was recently included in the Brentwood and ...
Breaking Biology Technology:
Cached News: